leadf
logo-loader
viewMaxCyte Inc

MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials

MaxCyte Inc (LON: MXCT) CEO Doug Doerfler sat down with Proactive at the BIO Investor Forum in San Francisco. 

Doerfler says the company is making 'exciting progress' with its early-stage cancer drug developed using its CARMA technology. 

The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.

Quick facts: MaxCyte Inc

Price: 335 GBX

AIM:MXCT
Market: AIM
Market Cap: £258.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

2 min read